Articles On Bioxyne (ASX:BXN)

The ASX slumped by over -1pc, as jitters about delayed rate cuts rattled markets Miner BHP confirmed  $60 billion bid for competitor Anglo American Gold stocks climbed, but all 11 sectors closed in the red   The ASX 200 declined sharply b...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

  The ASX close higher as unemployment rate came in lower than expected Miners rally, led by BHP as the giant released its Q3 report Nimy Resources up 50pc after reporting promising intercepts   The ASX added 0.5% on Thursday as the unemp...

Australian life sciences, pharmaceutical and consumer health products company Bioxyne (ASX:BXN) has received firm commitments to raise $1.45 million.

The ASX200 closed +0.5% higher on Tuesday on the back of a big lift in the Mining sector.  Lithium stocks led, with IGO (ASX:IGO) and Pilbara (ASX:PLS) gaining around 3%.  Iron ore miners  rallied after the Nymex CFR China, 62% Fe price swu...

This week’s Bulls N’ Bears top ASX runner is … Kula Gold. Its share price rose 100 per cent to join fellow movers and shakers Tali Digital, Bioxyne and Venture Minerals.

Bioxyne (ASX:BXN) has announced that its subsidiary, Breathe Life Sciences, has been awarded a Good Manufacturing Practice license for the production of medical cannabis.

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Bioxyne’s subsidiary imports 200kg of premium high THC cannabis flower across three strains into Australia Company is first company to import cannabis into Australia from the UK, the world’s biggest cannabis producer for medical and scient...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix   The ASX200 is up +0.4% at  the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l...

Benchmark index finds some rare greenage, up 0.5% Property and IT Sectors lead broad-based gains, XEC Emerging Co’s index now down 14% from July highs Fascinating small caps action: led by Dimerix, Bluglass and Experience Co.   The ASX2...

Benchmark index falls on Monday, closing out the day down 0.21% Utilities and Materials sectors edge higher, but Health Care anchors the benchmark into the red Small caps led by Galileo Mining, Infinity and last week’s rockstar Biotron...

Stockhead’s Top 10 at shortly-before-11-ish, produced through a blistering “I spent all weekend in the sun watching 1,500 kids play soccer” headache, and quietly praying for death. Top 10 highlights the best (and sometimes worst) performing...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Morgans says companies on the ASX are propelling our appetite product for health and wellness products Bioxyne says Covid has shown our susceptibility to disease, but also how resilient and strong we are in fighting it Anagenics says it’s...

In recent years, consumer preferences have undergone a notable shift towards alternative beverages that offer calming effects without the downsides associated with alcohol consumption. This trend presents a lucrative opportunity for inve...

ASX 200 ends sharply lower on Monday, down 0.67% All Sectors  close in the red, with InfoTech taking the worst of the damage Small caps led by lithium minnows RR1, WC8 and VCM Australian shares have joined most Asian markets in a retre...

ASX 200 closes 1.3% higher, adds 1.5% for the week All Sectors in the green following strong Chinese data drop Small caps led by OZM, uranium stocks   Australian shares have risen strongly on Friday following decent overnight leads from...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

  ASX 200 find 0.5% to start the week, LTR looks ready to sell Energy stocks and miners offset IT and Consumer Discretionary losses Small cap winners led by EMD and GLH   Local markets were led higher on Monday, supported by resource busi...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

ASX 200 closes about 0.5% higher after a half-decent lead in from Wall Street Material and Discretionary offset losses in Healthcare and IT  Small cap winners led by EML payments, GCX Metals   It was exciting stuff on Australian share ma...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s Top 10 at 11, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

 The ASX 200 benchmark has climbed down from highs at lunch to finish on +0.39%. Health Care was well out in front of the market all day, thanks to a chunky bump for CSL. Voltaic Strategic Resources won the Small Caps Cup, rising 22.5% for...

Bioxyne subsidiary Breathe Life Sciences has joined forces with CanXChange to facilitate wholesale trading in Australia’s growing cannabis market. Bioxyne’s (ASX:BXN) wholly-owned subsidiary Breathe Life Sciences (BLS) and tech company Can...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX closed down 0.58 per cent. All sectors except communications traded down. Helping to boost consumer staples stocks was healthy and beauty products company Bioxyne – up 20 per cent. While Aussie Broadband helped to lift comm...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

What a time to be alive. As the clock struck midnight to herald the start of the 23/24 financial year, Australia’s ability to legally prescribe through qualified medical practitioners MDMA (ecstasy) and psilocybin – the active ingredient in...

The ASX 200 built a platform for success today. Which failed. It fell flat at close Sectors wise, Financials, IT and Industrials did okay. The others, very much including Health Care and Utilities, didn’t Notable performers today: Nuix (AS...

ASX extended its losses for a second day running, ending 0.20% in the red Real Estate, Telcos, Industrials and Energy stonks led the losers, while Financials and Health Care get the teacher’s smiley stamps today The day’s clear winner was...

ASX chopped about sideways, losing any slight semblance of  fizz at close: -0.063% IT, Discretionary and Industrials led sectors, while Materials lagged The day’s clear winner was Mantle Minerals, up 50% at day’s end on further exploration...

Stock Insiders is a podcast series focussed on investing, hosted by TV presenter and news journalist Christina Morrissy.  In this episode Christina chats to Sam Watson, co-CEO at Bioxyne Limited (ASX:BXN). Bioxyne recently announced it hit...

The ASX200 closed up 0.38 per cent today. Energy and materials stocks were the strongest performers, while healthcare, tech stocks, comms, consumer staples and utilities lost ground. The Reserve Bank’s Governor Philip Lowe said he wo...

ASX  gains 0.46% while the emerging companies index falls RBA board will meet eight times instead of 11 times annually to set interest rates Nickel Search again intersects massive sulphide mineralisation at the Sexton prospect   After e...

ASX snaps a 4-day run of bruising luck with a welcome 1.5% gain Techies did a lot of the heavy lifting, while the Goldies put on a +3.54% show The day’s clear winner was Mobilicom, up 150% at day’s end on juicy defence news   Local market...

The ASX 200 is down nearly 0.5 per cent at market close, declining throughout the day after a strong start.  Information Technology was the only sector to hold up in the green, with Vista Group, Echo IQ, Bigtincan Holdings, Orcoda, ArchT...

ASX dips 0.56% despite a solid kickstart first thing this morning InfoTech outperforms the market again, leading on +0.21% for the day Heavy Minerals banks a 90% bump on some big time garnet news   For 10 fantastic minutes this morning, l...

Bioxyne’s acquisition of Breathe Life Sciences is paying off with its well-established Dr Watson® brand of cannabis products continuing to be a consumer favourite. Healthcare company Bioxyne (ASX:BXN) has announced it hit a $1 million annu...

ASX 200 benchmark climbs 0.65% despite a sour lead-in from Wall Street and Europe. Real Estate sector banks solid wins after shopping centres put on a big day.  Forrestania Resources hits 162% on thick pegmatite news, but the ASX has asked...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Bioxyne’s acquisition of Breathe Life Sciences (BLS) gives it a new, readymade consumer-facing pathway, positioning the company for strong growth both in Australia and globally.  Healthcare company Bioxyne (ASX:BXN) said it has entered int...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

The ASX continued its tragic decline, falling 1.05% over the course of a rubbish day InfoTech took trend-bucking to a whole new level, outperforming the market by 3.5% Something’s up at IncentiaPay, because it’s climbed 71.4% on absolutely...